LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Apellis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

17.78 -2.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.66

Max

18.31

Galvenie mērījumi

By Trading Economics

Ienākumi

-56M

-92M

Pārdošana

-46M

167M

EPS

-0.74

Peļņas marža

-55.292

Darbinieki

705

EBITDA

-56M

-80M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+101.26% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 31. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-190M

2.4B

Iepriekšējā atvēršanas cena

20.73

Iepriekšējā slēgšanas cena

17.78

Apellis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. jūn. 14:44 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

2025. g. 17. jūn. 23:43 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

2025. g. 17. jūn. 23:34 UTC

Tirgus saruna

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

2025. g. 17. jūn. 23:17 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

2025. g. 17. jūn. 23:05 UTC

Tirgus saruna

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

2025. g. 17. jūn. 23:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. jūn. 22:58 UTC

Tirgus saruna

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

2025. g. 17. jūn. 22:55 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

2025. g. 17. jūn. 22:31 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

2025. g. 17. jūn. 22:14 UTC

Galvenie tirgus virzītāji

Bitdeer Technologies Group Shares Fall on Note Offering

2025. g. 17. jūn. 19:49 UTC

Tirgus saruna

Natural Gas Slow Down Gains -- Market Talk

2025. g. 17. jūn. 19:34 UTC

Tirgus saruna

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

2025. g. 17. jūn. 19:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. jūn. 19:10 UTC

Tirgus saruna

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

2025. g. 17. jūn. 18:41 UTC

Tirgus saruna

Slowdown in US Consumer Spending Expected -- Market Talk

2025. g. 17. jūn. 18:15 UTC

Tirgus saruna

Gold Inches Down as Profit-Taking Seen -- Market Talk

2025. g. 17. jūn. 17:44 UTC

Tirgus saruna

Analysts Forecast Record-High Ethanol Output -- Market Talk

2025. g. 17. jūn. 16:37 UTC

Tirgus saruna

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

2025. g. 17. jūn. 16:30 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 17. jūn. 16:30 UTC

Tirgus saruna

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

2025. g. 17. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 17. jūn. 16:15 UTC

Tirgus saruna

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

2025. g. 17. jūn. 16:12 UTC

Tirgus saruna

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

2025. g. 17. jūn. 14:54 UTC

Tirgus saruna

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

2025. g. 17. jūn. 14:47 UTC

Tirgus saruna

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

2025. g. 17. jūn. 14:41 UTC

Tirgus saruna

Natural Gas Extends Climb -- Market Talk

2025. g. 17. jūn. 14:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Apellis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

101.26% augšup

Prognoze 12 mēnešiem

Vidējais 36.83 USD  101.26%

Augstākais 60 USD

Zemākais 18 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Apellis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

20 ratings

12

Pirkt

8

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.